Rebiotix

Rebiotix Inc. has announced it has received FDA approval on its Investigational New Drug (IND) application to begin a Phase 2 clinical study of a treatment of recurrent Clostridium difficile infection (CDI). The treatment, cialis RBX2660, ask is a “preparation containing live microbes designed to rebuild a healthy intestinal micro biome.” ┬áIf successful, the treatment […]

{ 0 comments }

Continue Reading